Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Presidio Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013970
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Presidio Pharmaceuticals Inc (Presidio) is a clinical-stage pharmaceutical company that discovers and develops small-molecule antiviral therapeutics. The company’s products include HCV NS5A, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride, protease inhibitor, faldaprevir and non-nucleoside inhibitor. Presidio’s lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride has completed phase 1 clinical studies in both healthy volunteers and HCV patients. Its second pan-genotypic HCV inhibitor PPI-383 is a NS5B non-nucleoside inhibitor currently being evaluated in phase 1 studies. The company also has an extensive intellectual property portfolio for its HCV programs. Presidio is headquartered in San Francisco, California, the US.

Presidio Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 10
Presidio Pharma Raises US$8.6 Million In Series D Financing 11
Presidio Pharma Raises Additional US$8 Million In Series C Financing 12
Presidio Pharma Secures US$3 Million In Venture Financing 13
Licensing Agreements 14
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 14
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 15
Presidio Pharmaceuticals Inc – Key Competitors 16
Presidio Pharmaceuticals Inc – Key Employees 17
Presidio Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Presidio Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 10
Presidio Pharma Raises US$8.6 Million In Series D Financing 11
Presidio Pharma Raises Additional US$8 Million In Series C Financing 12
Presidio Pharma Secures US$3 Million In Venture Financing 13
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 14
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 15
Presidio Pharmaceuticals Inc, Key Competitors 16
Presidio Pharmaceuticals Inc, Key Employees 17

★海外企業調査レポート[Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OmniGuide Inc:医療機器:M&Aディール及び事業提携情報
    Summary OmniGuide Inc (OmniGuide) is a medical device company that offers microsurgery, laparoscopy, and robotic assisted surgery products. The company’s products comprise GYN systems, ENT systems, OTO systems, line of sight systems, robotic surgical products and others. It also offers gynecology su …
  • China Gezhouba Group Co Ltd (600068):電力:M&Aディール及び事業提携情報
    Summary China Gezhouba Group Co Ltd (CGGC) is an engineering, procurement and construction (EPC) company. It provides a wide range of services including dredging, foundation works, building construction, engineering survey, designing, construction management and consultancy, and relevant technology …
  • AutoGenomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary AutoGenomics Inc (AutoGenomics) is a provider of automated technologies for test processes inherent in genetic analysis. The company offers infiniti systems and FDA cleared products and RUO products. Its infiniti system is designed for processing AutoGenomics' unique proprietary BioFilmChip …
  • SM Energy Co (SM):石油・ガス:M&Aディール及び事業提携情報
    Summary SM Energy Co (SM Energy) is an independent upstream oil and gas company. It carries out the acquisition, exploration, development, and production of crude oil, natural gas and natural gas liquids (NGLs) in onshore North America. The company’s operations are concentrated in three onshore oper …
  • Sotera Health LLC:医療機器:M&Aディール及び事業提携情報
    Summary Sotera Health LLC (Sotera Health), formerly Sterigenics International LLC, a subsidiary of GTCR LLC, is a medical device company. The company offers sterilization technologies such as gamma irradiation, electron beam and ethylene oxide. Its services include drug device combination, vaccine s …
  • Celldex Therapeutics Inc (CLDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops and commercializes targeted immunotherapy technologies and cancer-targeting biologicsfor the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodie …
  • International Paper Co:戦略・SWOT・企業財務分析
    International Paper Co - Strategy, SWOT and Corporate Finance Report Summary International Paper Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ALSO Holding AG:企業の戦略・SWOT・財務情報
    ALSO Holding AG - Strategy, SWOT and Corporate Finance Report Summary ALSO Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Cleveland HeartLab Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cleveland HeartLab Inc (Cleveland HeartLab) is a clinical laboratory that provides cardiovascular testing services. The laboratory offers services such as cardiovascular risk assessment, novel diagnostic tests, inflammatory and other advanced biomarker testing, management and prevention of h …
  • Saudi Arabian Mining Co:戦略・SWOT・企業財務分析
    Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report Summary Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Colonial Pipeline Company:石油・ガス:M&Aディール及び事業提携情報
    Summary Colonial Pipeline Company (Colonial) is an oil and gas company that distributes petroleum products. The company transports refined petroleum products such as gasoline, home-heating oil, kerosene, diesel fuels; and aviation fuel including jet fuel and military fuels. It provides services incl …
  • IntraPace Inc:医療機器:M&Aディール及び事業提携情報
    Summary IntraPace Inc (IntraPace) is a medical device company that develops novel implantable systems. The company offers abiliti systems that contain sensors intended to track consumption events and physical activity to direct when therapy is delivered and to monitor a patient's progress toward wei …
  • Patheon NV:戦略・SWOT・企業財務分析
    Patheon NV - Strategy, SWOT and Corporate Finance Report Summary Patheon NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務分析
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Toei Animation Co., Ltd.:企業の戦略・SWOT・財務分析
    Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sanofi Genzyme:企業のM&A・事業提携・投資動向
    Sanofi Genzyme - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sanofi Genzyme Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Eli Lilly and Co (LLY)-医療機器分野:企業M&A・提携分析
    Summary Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men's health and musculoskeletal problems. It a …
  • Bank Pekao SA:戦略・SWOT・企業財務分析
    Bank Pekao SA - Strategy, SWOT and Corporate Finance Report Summary Bank Pekao SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Zucara Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Zucara Therapeutics Inc (Zucara Therapeutics) is a pharmaceutical company that develops novel drug therapies to prevent hypoglycemia in people with diabetes. The company’s technology is used to prevent the dangerous low blood sugar by restoring the body’s ability to counter-regulate hypoglyc …
  • Katara Hospitality:企業の戦略・SWOT・財務分析
    Katara Hospitality - Strategy, SWOT and Corporate Finance Report Summary Katara Hospitality - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆